Juventas Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cleveland OH United States (2007)
Status: Defunct (2022)

Organization Overview

First Clinical Trial
2010
NCT01082094
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Juventas Cell Therapy Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Juventas Therapeutics, Inc. (0) Acquired (2)

morphine (1 trial)

sufentanil (17 trials)

Drugs in Phase 2 Trials (10)

Key: Juventas Therapeutics, Inc. (9) Acquired (1)

busulfan (Myleran) (1 trial)

cd19 car-t cells (2 trials)

cnct19 (5 trials)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

gemcitabine (gemzar) (1 trial)

hy004 (2 trials)

jvrs-100 (4 trials)

melphalan (alkeran) (1 trial)

triazolam (halcion) (1 trial)

Drugs in Phase 1 Trials (3)

Key: Juventas Therapeutics, Inc. (2) Acquired (1)

acrx-100 (1 trial)

autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)

ketoconazole (nizoral) (1 trial)

Drugs in Other Trials (1)

hiv-1 specific car-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 2)

Ischemia (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Neoplasms (Phase 1)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 33
  • # of Trial APIs: 16